# Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

> **NCT02209376** · PHASE1 · TERMINATED · sponsor: **University of Pennsylvania** · enrollment: 11 (actual)

## Conditions studied

- Patients With Residual or Reccurent EGFRvIII+ Glioma

## Interventions

- **BIOLOGICAL:** CART-EGFRvIII T cells

## Key facts

- **NCT ID:** NCT02209376
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-18
- **Primary completion:** 2018-04-04
- **Final completion:** 2018-04-04
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate prior to completion to pursue combination therapies.
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02209376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02209376, "Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02209376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*